Lastly, adjunct anti-inflammatory therapies, such as statins and canakinumab, are suggested to reduce the burden of DCM, possibly by alleviating IL1β-dependent insulin resistance in metabolic disorders (Gao and Ye, 2012; Liberale et al., 2019). Here, IL1B is linked to familial dilated cardiomyopathy.